Post-marketing review highlights safety gaps for migraine CGRP drugs

This narrative review examines monoclonal antibodies and Calcitonin Gene-Related Peptide inhibitors used for migraine. The study looks at these drugs after they have been on the market. Data on these treatments is currently scarce. The review points out that experience before marketing approval was limited. Additional risks exist because these are biologic compounds. Chronic use of most of these drugs also presents unknown long-term issues. The authors note that active pharmacovigilance aims to fill gaps using continuous processes. These processes help identify adverse events that may have been missed earlier. Readers should understand that more information is needed before these drugs are fully understood. The main reason to be careful is the lack of complete safety data. This review does not provide specific medical advice or recommend these treatments. It serves to highlight the need for ongoing monitoring and research.